Evgen Pharma PLC (EVG.L) WACC Analysis

As of May 23, 2025, Evgen Pharma PLC (EVG.L) carries a Weighted Average Cost of Capital (WACC) of 6.4%. WACC reflects the blended rate Evgen Pharma PLC must pay to both equity and debt holders.

Within that, the cost of equity is 6.9%, the cost of debt is 5.0%, and the effective tax rate is 15.2%.

Breakdown of WACC Components

• Long-term bond rate: 3.7% – 4.2%
• Equity market risk premium: 6.0% – 7.0%
• Adjusted beta: 0.52 – 0.81
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 1

What It Means for Investors

With a selected WACC of 6.4%, Evgen Pharma PLC must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.